<DOC>
	<DOCNO>NCT01687257</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy combination therapy sofosbuvir ( SOF ) plus ribavirin ( RBV ) 48 week adults compensate decompensated chronic hepatitis C virus ( HCV ) infection . Approximately 50 adult randomize ( 1:1 ) receive study drug 48 week take part untreated observational arm first 24 week follow study drug another 48 week .</brief_summary>
	<brief_title>Sofosbuvir Ribavirin Patients With Chronic HCV With Cirrhosis Portal Hypertension With Without Liver Decompensation</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic infection Hepatitis C HCV RNA &gt; 1000 IU/mL Individuals cirrhosis ChildPugh score &lt; 10 Esophageal gastric varix endoscopy within 6 month prior screen Hepatic Venous Pressure Gradient ( HVPG ) &gt; 6 mmHg Body mass index ( BMI ) ≥ 18 kg/m^2 Naïve nucleotides/nucleoside treatment chronic HCV infection Have serious active medical psychiatric illness , opinion investigator , would interfere subject treatment , assessment , compliance HIV chronic hepatitis B virus ( HBV ) infection ( HBsAg positive ) Alphafetoprotein ( AFP ) &gt; 50 unless negative imaging hepatic mass within last 6 month screen Refractory ascites define require paracentesis &gt; twice within 1 month prior screen Active variceal bleed within 6 month screen Expected survival &lt; 1 year History hepatorenal , hepatopulmonary syndrome . Evidence renal impairment ( CrCl &lt; 50 mL/min ) History major organ transplantation , include liver transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>